Latest News and Press Releases

MCDONALD, Tenn., July 22, 2026 (GLOBE NEWSWIRE) -- Amaero Inc. (ASX:3DA) (“Amaero” or the “Company”), a leading U.S. domestic producer of high-value refractory alloy and titanium powders for...

Dublin, July 10, 2026 (GLOBE NEWSWIRE) -- The "AI in Orthopedic Surgery Market Report 2026" has been added to ResearchAndMarkets.com's offering. The artificial intelligence (AI) in orthopedic...

Dublin, July 09, 2026 (GLOBE NEWSWIRE) -- The "Global Orthopedic Surgical Robots Market" has been added to ResearchAndMarkets.com's offering. This report offers an in-depth analysis of the...

Regulatory Milestone Advances First-in-Class Non-Invasive Technology Targeting a Multi-Billion-Dollar Orthopedic Infection Market Clinical Site Activation Across Leading Centers in the U.S. and...

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to...

New York, USA, June 15, 2026 (GLOBE NEWSWIRE) -- Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and...

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613...

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later...

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted...

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed...